References
- Rosenberg S A, Lotze M T, Muul L M, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–1492
- Klein G. Tumor antigens. Ann Rev Microbiol 1967; 223–252
- Hellstrom I, Helstrom K E, Pierce G E, Yang J PS. Cellular and humoral immunity to different types of human neoplasms. Nature 1968; 220: 1352–1354
- Esber H J, DeCourcy S J, Jr, Bogden A E. Specific and nonspecific immune resistance enhancing activity of staphage lysate. J Immunopharmacol 1981; 3: 79–92
- Salmon G G, Symonds M. Staphage lysate therapy in chronic staphylococcal infections. J Med Soc NJ 1963; 60: 180–193
- Kress D W, Graham W P, Davis T S, Miller S H. A preliminary report on the use of staphage lysate for treatment of hidradenitis suppurativa. Ann Plast Surg 1981; 6: 393–395
- Mackaness G B. The immunological basis of acquired cellular resistance. J Exp Med 1964; 120: 105–120
- Mudd S. Resistance against Staphylococcus aureus. JAMA 1981; 218: 1671–1673
- Esber H J, Ganfield D, Rosenkrantz H. Staphage lysate: An immunomodulator of the primary immune response in mice. Immunopharmacol 1985; 10: 77–82
- Shayegoni M, Lief F S, Mudd S. Specific and non-specific cell-mediated resistance to influenza virus in mice. Infect Immun 1974; 9: 991–998
- Baker A G. Staphylococcus bacteriophage lysate. Topical and parenteral use in allergic patients. Penn Med J 1963; 66: 25–28